BioStock: Emplicure steams towards key milestones in Amp01 and Empli03

Emplicure’s report for the first quarter of 2022 puts the emphasis on the preparations for the pharmacokinetic study with the main project Empli03. The formulation has been finalised; documentation, methods, and specifications have been transferred to the company’s research partner (CRO/CDMO) in the UK and the active ingredient has been secured. At the same time, the company are advancing the nicotine products within the Amp01 project. BioStock spoke to CEO Torbjörn W. Larsson for a comment on the first quarter.

Read the full interview at biostock.se:

https://www.biostock.se/en/2022/05/emplicure-steams-towards-key-milestones-in-amp01-and-empli03/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se